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15-DEOXYSPERGUALIN (DSPG) is a 
new antitumor and immunosuppressive 
agent derived from the antibiotic spergualin. 
This agent was shown to prolong the graft 
survival of skin, heart, pancreas islet, kidney, 
and liver in the rodent. I-3 No observations 
have been made with large animals. In the 
present study, the effect of DSPG was first 
tested with rat heterotopic heart transplanta-
tion (HTX) and then evaluated with canine 
kidney transplantation (KTX). 
MATERIALS AND METHODS 
Animals 
Lewis rats (RT I) purchased fwm the Harlan Spraque 
Dawley Company (Indianapolis) were used as recipients. 
ACI rats (RT 1') were purchased from the Simonsen Lab 
(Gilcoy, CAl and used as donors. 
Outbred beagle dogs were obtained from the Univer-
sity of Pittsburgh farm and were used as both donors and 
recipients. 
Operative Procedures 
HTX was performed by the method of Ono and Lind-
say.' The donor aorta and pulmonary artery were anasto-
mosed to the recipient aorta and infrarenal inferior vena 
cava with standard microvascular techniques. KTX was 
performed by conventional intra-abdominal techniq)les, 
with which the renal artery was anastomosed to the 
recipient iliac artery end-to-end and the renal vein was 
anastomosed to the recipient iliac vein end-to-side. Bilat-
eral native nephrectomy was performed after graft urete-
ro-neocystostomy. 
Drug Administration 
DSPG was supplied as a powder from the Nippon 
Kayaku Company, Ltd, Tokyo. It was dissolved in saline, 
and was given intra peritoneally to the rat for 2 weeks and 
intravenousiy to the dog for 50 days starting immediately 
after the transplant operation. In experiments with drug 
combinations in dogs, cyclosporine (CyA) was given 
orally in the commercial oil carrier that is used clinically. 
Oral prednisone (Pred) was given to dogs as a 5-mg 
tablet. 
Experimental Groups 
Intraperitoneal doses tested in HTX were 0.0 mg/kg/d 
(control), 0.5 mg/kg/d, 1.0 mg/kg/d, 3.0 mg/kg/d, and 
6.0 mg/kg/d. Treatment was for 14 days beginning just 
after the operation. Rejection was diagnosed by the 
cessation of heartbeat and was confirmed visually by 
laparotomy and histologic examination. 
The effect of intravenous DSPG alone and in combina-
tion with oral CyA and Pred on KTX were examined in 
the following groups: 
I. Dose-effectiveness study 
Group I: (N ~ 6) DSPG (0.0 mg/kg/d) 
Group 2: (N ~ 6) DSPG (0.25 mg/kg/d) 
Group 3: (N ~ 6) DSPG (0.5 mg/kg/d) 
Group 4: eN ~ 6) DSPG (0.75 mg/kg/d) 
Group 5: (N ~ 6) DSPG (1.0 mg/kg/d) 
2. Combination study 
Group 6: (N ~ 10) DSPG (0.5 mg/kg/d) + CyA 
(5 mg/kg/d) + Pred (5 mg/d) 
Group 7: (N ~ 6) DSPG (0.5 mg/kg/d) + CyA 
(5 mg/kg/d) 
Group 8: (N ~ 6) DSPG (0.5 mg/kg/d) + Pred 
(5 mg/d) 
Group 9: (N ~ 6) CyA (5 mg/kg/d) + 
Pred (5 mg/d) 
Group 10: (N ~ 6) CyA (5 mg/kg/d) 
Group II: (N ~ 6) Pred (5 mg/d) 
Because of emaciation of animals, the dose of DSPG in 
the combination experiments was reduced to 0.3 mg/ 
kg/d after 3 weeks and to 0.2 mg/kg/d after 6 weeks. 
Blood samples were collected every three mornings for the 
determination of kidney and liver functions. Complete 
postmortem examination of animals was performed. His-
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Table 1. Survival of Grafts by Intraperitonaallnjection of DSPG 
Dose Animals Died Median P Animals Died 
Group (mg/kg/d) No. of Rejection (Day) (Dayl kl of Infection 
0.0 6 6,6,6,7,7 6 0/6 
2 0.5 5 19,20,25,29,46 25 0.01 0/5 
3 1.0 6 22,27,27,35,40 27 0.Q1 1/6 
4 3.0 6 30,32 
5 6.0 6 
NOTE. DSPG was given from day 0 to day 13 (14 days total). 
tologic severity of graft rejection was determined blindly 
basing on subjective scales from 0 to + + +. 
Statistics 
Wilcoxon rank sum test and Student's t test were 
applied for the statistical analysis. 
RESULTS 
HTX 
The median graft survival of untreated rats 
was six days (Table 1). Intraperitoneal OSPG 
administration at doses of 0.5 mg/kg/d and 
1.0 mg/kg/d provided significant prolonga-
tion of graft survivaL Higher doses were 
lethaL Four of six rats in group 4 and all 
animals in group 5 died of bronchopneumonia 
even though the grafts were beating. Colony 
contamination with pathogens could not be 
shown by serologic and microbiologic study of 
nontransplanted rats from the same labora-
tory environment. Thus, the deaths were 
attributed to over immunosuppression. 
4/6 
6/6 
KTX 
Dose-effectiveness study. Mean survival 
was 13.3 ± 3.6 (SO) days in untreated control 
dogs, (Fig 1) while that of treated dogs 
(groups 2 to 5) was variable. Significant pro-
longation of graft survival was obtained only 
with a dose of 0.75 mg/kg/d, group 4 (Fig 1), 
even though higher doses prevented creatinine 
(Cr) elevation (Fig 2) and even though histo-
logic evidence of rejection was reduced at 
higher doses. The last Cr prior to animal 
death was 15.0 ± 4.6 (SO) mg/dL in group 1, 
11.3 ± 3.8 in group 2, 5.4 ± 1.5 in group 3, 
2.7 ± 2.8 in group 4; and 5.1 ± 3.4 in group 5. 
The prevention of Cr rise was significant in 
animals treated with 0.5 mg/kg/d or more of 
OSPG compared to groups 1 and 2. All ani-
mals given 1.0 mg/kg/ d of OSPG died of 
lethal emacrrttion accompanied with severe 
diarrhea. Liver dysfunction was not observed 
in any group. Pulmonary congestion was the 
only pathologic abnormality in the extrarenal 
organs seemingly related to animal death. 
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Fig 2. Changes in serum creatinine of KTX dogs treated with different doses of DSPG. 
Drug combination. The results were com-
pared with those in group 3 in which 0.5 
mg/kg/d DSPG alone prolonged survival 
from 2 to about 3 weeks. The addition of 5 
mg/kg/d CyA with (group 6) or without 
prednisone (group 7) augmented this effect, 
but not beyond what could be achieved with 
CyA alone (Group 10) or CyA plus predni-
sone (group 9) (Fig 3). Thus, a clean-cut 
synergistic effect of DSPG with these other 
agents was not demonstrable. 
The best results were with cyclosporine, 
steroids, and DSPG. Elevation of Cr was well 
inhibited in this group of animals even though 
they died during the treatment. Emaciation 
and diarrhea were prominent in animals that 
were treated with DSPG for more than 3 
weeks. Consequently, the dose of DSPG had 
to be reduced. Complete histopathologic anal-
yses in animals subjected to the combination 
study has not yet been completed, but a pre-
liminary observation is that rejection was 
absent or minimal in dogs under triple drug 
treatment. 
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DISCUSSION 
The present study is the first demonstration 
that DSPG inhibits the rejection of canine 
kidney homografts. However, the immuno-
suppressive effect of DSPG alone was feeble 
and the toxicity was unacceptable. Doses of 
0.75 mg/kg/d had a minor therapeutic affect 
but not enough to yield long animal survival. 
Doses higher than this caused the dogs to die 
of lethal emaciation. 
Toxicity was somewhat less in rats. How-
ever, in contrast to the observation by oth-
ersY most of our rats given higher doses of 
DSPG died from bronchopneumonia. No 
pathogen could be identified. The findings 
were different than those of Ochia et al3 who 
reported universal survival of WKA rats for 
more than 80 days, using the much higher 
dose of 10 mg/kg/ d intramuscularly. Sensi-
tivity of rats to DSPG may differ among 
strains. 
Combination therapy is a potential alterna-
tive method with which the toxicity of DSPG 
could be avoided if a reduced dose would work 
synergistically with other agents. These hopes 
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were not encouraged by actual experiments. 
Toxicity of DSPG persisted and the principal 
immunosuppression was from the CyA, which 
was an ingredient of the "cocktail." Thus, our 
results suggest that DSPG alone or in combi-
nation probably will not be useful for clinical 
immunosu ppression. 
Before pushing ahead with more experi-
ments, it may be wise to learn more of the 
mechanism of DSPG. DSPG has been said to 
inhibit the macrophage/phagocyte system 
instead of affecting lymphocytes.2 However, 
there are no well documented experiments to 
support this contention. Until such evidence is 
available, further attempts to combine DSPG 
with other agents are apt to be unrewarding. 
SUMMARY 
DSPG had a definite but relatively feeble 
immunosuppressive effect in rats undergoing 
heterotopic heart transplantation and in dogs 
after renal transplantation. The drug was 
toxic in both species, although less so in rats. 
In dogs, synergistic interactions with cyclo-
sporine and steroids were not evident. 
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